Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl–mediated drug resistance
Jennifer S. Carew(University of Arizona), John L. Cleveland(Moffitt Cancer Center), Charissa N. Kahue(Chaminade University of Honolulu), Francis J. Giles(National University of Ireland), Steffan T. Nawrocki(University of Arizona), Chunying Yang, Hui Zhang(Capital Medical University), Peng Huang(Wildlife Conservation Society), Janet A. Houghton(Cleveland Clinic), Linda H. Chung
Cited by 485
Related Papers
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes
|Autophagy|2008|2k
Targeting lactate metabolism for cancer therapeutics
|Journal of Clinical Investigation|2013|1.2k
Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia
|Journal of Clinical Oncology|2005|951
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782